Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Crohn's Disease (Mar 2021)

Posted by Matt Breese on Mar 5, 2021

Find me on:

According to our recent payer coverage analysis for Crohn's disease treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for Crohn's disease treatments shows that under the pharmacy benefit, almost 57% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Crohns Disease-1Q2021Data snapshot as of Q1 2021

Trends: New-to-market products should expect stiff competition due to the number of originator biologics and biosimilars available and in the pipeline. Also, with most products demonstrating similar clinical efficacy, with the exception of anti-tumor necrosis factor agents, which stand out as preferred biologics in clinical guidelines, patient cost will be a determining factor for prescribers; therefore, contracting remains extremely important for market success.    

To read the full Reality Check on Crohn's Disease treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing